PUBLICATIONS

FAQs

About Nafdac

In accordance with the enabling laws, NAFDAC is authorised to:
• Regulate and control the importation, exportation, manufacture, advertisement, distribution, sale and use of regulated products. 
• Conduct appropriate tests and ensure compliance with standard specifications. 
• Undertake appropriate investigation of the production premises and raw materials of regulated products. 
• Compile standard specifications, regulations, and guidelines for the production, importation, exportation, sale and distribution of regulated products.

Our Vission and Mission

  VISION

Safeguarding public health

MISSION STATEMENT

To safeguard public health by ensuring that only the right quality drugs, food and other regulated products are manufactured, imported, exported, advertised, distributed, sold and used.

end faq 

CONSUMER ALERTS

The National Agency for Food and Drug Administration and Control (NAFDAC) wishes to draw the attention of the general public to the regulatory action taken by the Agency on the following drugs, some of which have been banned /restricted internationally.

(HTML h3) What is a FAQ?
Content
.
.
(HTML h3) What is Accordion FAQ? 
Content
.
.
(HTML h3) Module or Plugin? 
Content
.
.

And so on...until

 

(HTML h3) End FAQ(faq terminating line)

 

View More

• Report Adverse Drug Reaction                    • Send Us a Complaint

• Report Suspected Criminal Activity           • Send Us a Feedback

(HTML h3) CONSUMER ALERTS

(HTML h3)

PUBLIC ALERT NOTICE ON VALPROATE SODIUM

VALPROATE SODIUM  This is an anti-epileptic drug which is normally prescribed as a prophylactic medication.  It has been found to cause neural tube defects in children born to women who took this drug during pregnancy. The affected children suffer from what is known as "foetal anticonvulsant syndrome", or FACS, which causes a range of neural, behavioral and physical disorders. These disorders include; cleft palate and spinal bifida, learning difficulties, behavioral problems and abnormalities in movement, speech, vision and hearing.  In Nigeria, Epilim and Epivan, brands of sodium valproate are registered for use as anti-epileptic drugs. NAFDAC strongly advise that women within the reproductive (child bearing) age SHOULD NOT use this drug.  However, antiepileptic drugs, including valproate, could be administered to women of childbearing potential only if they are clearly shown to be essential in the management of their medical condition.

PUBLIC ALERT NOTICE ON CHLORZOXAZONE

  1. CHLORZOXAZONE is a centrally acting muscle relaxant which has been linked with hepatotoxicity, a rare but serious adverse drug reaction. Other adverse reactions that may be associated with the use of Chlorzoxazone include; gastrointestinal bleeding, drowsiness, dizziness, light headedness and malaise. Studies have also shown that there is no evidence of the superiority of the effectiveness of one muscle relaxant from another; however its combination with analgesics tends to produce superior pain killing effects than the single formulated muscle relaxant.

Currently, two brands of Chlorzoxazone are licensed for distribution in Nigeria by NAFDAC. One of the registered brands is a combination product, while the other brand is a mono-component product of Chlorzoxazone.

In view of the safety concerns on the use of Chlorzoxazone, healthcare providers are advised to prescribe and dispense this drug rationally. NAFDAC also wishes to advise healthcare providers to actively monitor the use of Chlorzoxazone in their patients with regards to its potential to precipitate hepatotoxicity.

PUBLIC ALERT NOTICE ON AVASTIN

  1. AVASTIN is a drug that was approved for the treatment of breast cancer. Investigations by the US FDA have shown that patients on Avastin experienced high blood pressure and fatigue. A follow up investigation by the manufacturer, Roche also revealed that the drug does not significantly prolong the lives of patients when compared to chemotherapy. The US FDA has proposed a ban of the drug due to the observed serious side effects and its failure to slow tumor growth or help breast cancer patients. In view of the current findings on Avastin, NAFDAC is closely monitoring the safety/efficacy of this drug with a view to determining appropriate regulatory action. NAFDAC also wishes to advise all healthcare practitioners to closely monitor the use of Avastin and report any observed adverse effects to the National Pharmacovigilance Centre, NAFDAC Abuja.

ONLINE PORTALS

napams

Contact Us from Mon - Friday: 08:00-16:00 GMT+1

Write Us:

NAFDAC Corporate Headquarters,

Plot 2032, Olusegun, Obasanjo Way,

Zone 7, Wuse, Abuja, Nigeria

 

Lagos Operation Office:

Plot 1, Industrial Estate, Lagos- Oshodi Apapa Express Way, Isolo, Lagos, Nigeria

 

 

 

 

 

 

For Enquiries:

Call: +234(0)-1-4609750

Email:nafdac@nafdac.gov.ng

 

 

 

 

 

 

 

 

 

 

 

For Complaints:

Call: +234(0)909-763-0506

         +234(0)909-763-0507

Email:reforms@nafdac.gov.ng

Or Send Us a Complaint

 

 

 

 

 

 

 

 

 

Contact Other NAFDAC Offices Nationwide